Premium
P2‐363: SERUM NEUROFILAMENT LIGHT PROTEIN AS A POTENTIAL BIOMARKER OF NEURODEGENERATION IN FORMER PROFESSIONAL ATHLETES WITH MULTIPLE CONCUSSIONS
Author(s) -
Taghdiri Foad,
Multani Namita,
Ozzoude Miracle,
Tarazi Apameh,
Naeimi Seyed Ali,
Khodadadi Mozhgan,
Wennberg Richard,
Mikulis David,
Green Robin,
Colella Brenda,
Davis Karen,
Blennow Kaj,
Tator Charles,
Tartaglia Carmela
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.2770
Subject(s) - neurodegeneration , corpus callosum , chronic traumatic encephalopathy , biomarker , medicine , cingulum (brain) , frontotemporal lobar degeneration , pathology , oncology , frontotemporal dementia , fractional anisotropy , diffusion mri , disease , magnetic resonance imaging , concussion , poison control , dementia , radiology , biology , biochemistry , environmental health , injury prevention
the Risk of Bias. Results: Main outcomes (differences between carriers and non-carriers on each imagingmodality) will be included in separate tables for each genetic group. Single case studies will be reported in the text. Measured cognitive deficits, expected age of onset of participants and differences between asymptomatic and symptomatic participants will be included if available. Conclusions: This systematic review will highlight to clinicians and researchers what are the earliest changes in the brains of pre-symptomatic carriers of FTD. It will also underline the strengths/weaknesses of current studies in the field and propose new avenues to future researchers.